Market News for Eli Lilly & Co (LLY)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Even though oncology, the segment in which the acquisition was made, has been lackluster in Q1 2025, it shows promise when seen over the longer term. In any case, there's a case for the company to diversify at a time when it's facing downward pressure on prices from policy, compounders, and fakes....
Seeking Alpha - 6/17/2025 8:46:34 AM
More News for LLY
Stock Analysis for LLY
Related Stocks:
